Placebo orally for 14 weeks
Sponsors
NOVARTIS BIOSCIENSES PERU S.A.,, MERCK SHARP & DOHME PERU S.R.L.,
Unknown Phase
A RANDOMIZED, 3-PERIOD, MULTI-DOSE, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND CONCENTRATION PROFILE IN PLASMA OF MONTELUKAST ADMINISTERED ONCE A DAY IN ORAL GRANULES TO CHILDREN FROM 1 TO 3 MONTHS OF AGE
Active, not recruitingPER-085-04
Target: 6Updated: 2023-09-04
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PARALLEL GROUP TO DETERMINE IF, IN PATIENTS WITH TYPE 2 DIABETES WITH HIGH RISK OF CARDIOVASCULAR AND RENAL EVENTS, ALISKIREN, IN ADDITION TO CONVENTIONAL TREATMENT, REDUCES MORBIDITY AND CARDIOVASCULAR AND RENAL MORTALITY
Active, not recruitingPER-079-07
Updated: 2023-09-04